- Portfolio of hemp-derived CBD products
- Opening of new production facilities
- New subsidiaries, acquisitions and joint ventures
Earth Science Tech, Inc. (OTC: ETST) is celebrating another year of accomplishment. In 2017, the company churned out a series of advancements that included the launch of new subsidiaries and products and an acquisition, along with entry into marketing, manufacturing and distribution agreements. It also commenced pre-launch human trials of a new product designed to join the fight against opioid addiction. As a result, 2017 revenues were almost twice as much as in 2016. Now, even though the stock is trading at around $1.00, a price target of over $4.00 has been set.
Earth Science is making waves in the hemp-derived cannabinoid (CBD), nutraceutical, pharmaceutical and medical device markets. The company’s activities range from R&D to production to marketing and distribution. It continues to build the networks and infrastructure to launch new products, embarking on a number of joint ventures and acquisitions, and launching new subsidiaries. It has created a new division, Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent.
Read the full article